Influenza virus type B

• POP BIO receives a $2.84M Phase II SBIR grant from NIAID to develop SNAP-Flu, a hexavalent influenza vaccine using its SNAP technology. • The SNAP-Flu vaccine utilizes nanoliposomes with a cobalt-porphyrin moiety and TLR4-based adjuvant to display multiple influenza antigens. • Preclinical studies will assess SNAP-Flu's protection against influenza strains in mice, ferrets, and non-human primates, comparing it to existing vaccines. • The grant supports expanding the SNAP platform for novel influenza antigen designs, paving the way for clinical trials and antigen-sparing vaccine formulations.

• The WHO has identified 17 endemic pathogens for which new vaccines are urgently needed, prioritizing based on factors like antimicrobial resistance and socioeconomic impact. • Pathogens such as Group A streptococcus and Klebsiella pneumoniae are highlighted as top priorities for disease control across all regions. • Vaccines for these pathogens are at various stages of development, with some nearing regulatory approval and others requiring further research. • This initiative aims to shift global vaccine development decisions towards addressing the needs of vulnerable communities and reducing healthcare costs.

• The FDA has approved FluMist, a nasal spray flu vaccine, for self-administration, marking the first flu vaccine that can be administered at home. • FluMist is approved for individuals aged 2 to 49 and will be available through an online pharmacy with a prescription, starting next flu season. • The approval is based on studies showing that adults can safely and effectively administer the vaccine themselves or to children with proper instructions. • This new option aims to improve convenience, flexibility, and accessibility to seasonal influenza vaccination, potentially increasing vaccination rates.